Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant.
The American Society of Clinical Oncology elected Elizabeth A. Mittendorf to lead as its president beginning in June 2026. Mittendorf, a long-time ASCO member and volunteer, will take office as president-elect immediately following the ASCO Annual Business Meeting in Chicago on June 2.
